The Metabolic Syndrome and Biochemical Recurrence following Radical Prostatectomy
Jennifer M. Post
Karmanos Cancer Institute, Wayne State University, Detroit, MI 48201, USA karmanos.org
Department of Oncology, Wayne State University, Detroit, MI 48201, USA wayne.edu
Search for more papers by this authorCorresponding Author
Jennifer L. Beebe-Dimmer
Karmanos Cancer Institute, Wayne State University, Detroit, MI 48201, USA karmanos.org
Department of Oncology, Wayne State University, Detroit, MI 48201, USA wayne.edu
Search for more papers by this authorHal Morgenstern
Departments of Epidemiology and Environmental Health Sciences and Comprehensive Cancer Center, University of Michigan, Ann Arbor, MI 48103, USA umich.edu
Search for more papers by this authorChristine Neslund-Dudas
Department of Biostatistics and Research Epidemiology, Henry Ford Hospital, Detroit, MI 48310, USA henryford.com
Search for more papers by this authorCathryn H. Bock
Karmanos Cancer Institute, Wayne State University, Detroit, MI 48201, USA karmanos.org
Department of Oncology, Wayne State University, Detroit, MI 48201, USA wayne.edu
Search for more papers by this authorNora Nock
Department of Epidemiology and Biostatistics, Case Western Reserve University, Cleveland, OH 44109, USA case.edu
Search for more papers by this authorAndrew Rundle
Departments of Epidemiology, Columbia University Mailman School of Public Health, New York, NY 10032, USA columbia.edu
Search for more papers by this authorMichelle Jankowski
Department of Biostatistics and Research Epidemiology, Henry Ford Hospital, Detroit, MI 48310, USA henryford.com
Search for more papers by this authorBenjamin A. Rybicki
Karmanos Cancer Institute, Wayne State University, Detroit, MI 48201, USA karmanos.org
Department of Biostatistics and Research Epidemiology, Henry Ford Hospital, Detroit, MI 48310, USA henryford.com
Search for more papers by this authorJennifer M. Post
Karmanos Cancer Institute, Wayne State University, Detroit, MI 48201, USA karmanos.org
Department of Oncology, Wayne State University, Detroit, MI 48201, USA wayne.edu
Search for more papers by this authorCorresponding Author
Jennifer L. Beebe-Dimmer
Karmanos Cancer Institute, Wayne State University, Detroit, MI 48201, USA karmanos.org
Department of Oncology, Wayne State University, Detroit, MI 48201, USA wayne.edu
Search for more papers by this authorHal Morgenstern
Departments of Epidemiology and Environmental Health Sciences and Comprehensive Cancer Center, University of Michigan, Ann Arbor, MI 48103, USA umich.edu
Search for more papers by this authorChristine Neslund-Dudas
Department of Biostatistics and Research Epidemiology, Henry Ford Hospital, Detroit, MI 48310, USA henryford.com
Search for more papers by this authorCathryn H. Bock
Karmanos Cancer Institute, Wayne State University, Detroit, MI 48201, USA karmanos.org
Department of Oncology, Wayne State University, Detroit, MI 48201, USA wayne.edu
Search for more papers by this authorNora Nock
Department of Epidemiology and Biostatistics, Case Western Reserve University, Cleveland, OH 44109, USA case.edu
Search for more papers by this authorAndrew Rundle
Departments of Epidemiology, Columbia University Mailman School of Public Health, New York, NY 10032, USA columbia.edu
Search for more papers by this authorMichelle Jankowski
Department of Biostatistics and Research Epidemiology, Henry Ford Hospital, Detroit, MI 48310, USA henryford.com
Search for more papers by this authorBenjamin A. Rybicki
Karmanos Cancer Institute, Wayne State University, Detroit, MI 48201, USA karmanos.org
Department of Biostatistics and Research Epidemiology, Henry Ford Hospital, Detroit, MI 48310, USA henryford.com
Search for more papers by this authorAbstract
Metabolic syndrome refers to a set of conditions that increases the risk of cardiovascular disease and has been associated with an increased risk of prostate cancer, particularly among African American men. This study aimed to estimate the association of metabolic syndrome with biochemical recurrence (BCR) in a racially diverse population. Among 383 radical prostatectomy patients, 67 patients had documented biochemical recurrence. Hypertension was significantly, positively associated with the rate of BCR (hazard ratio (HR) = 2.1; 95% CI = 1.1, 3.8). There were distinct racial differences in the prevalence of individual metabolic syndrome components; however, the observed associations with BCR did not differ appreciably by race. We conclude that hypertension may contribute to a poorer prognosis in surgically treated prostate cancer patients. Our findings suggest that targeting components of the metabolic syndrome which are potentially modifiable through lifestyle interventions may be a viable strategy to reduce risk of BCR in prostate cancer.
References
- 1 Jemal A., Siegel R., Xu J., and Ward E., Cancer statistics, 2010, CA Cancer Journal for Clinicians. (2010) 60, no. 5, 277–300, 2-s2.0-77955635233, https://doi.org/10.3322/caac.20073.
- 2 Pound C. R., Partin A. W., Eisenberger M. A., Chan D. W., Pearson J. D., and Walsh P. C., Natural history of progression after PSA elevation following radical prostatectomy, Journal of the American Medical Association. (1999) 281, no. 17, 1591–1597, 2-s2.0-0033526309, https://doi.org/10.1001/jama.281.17.1591.
- 3 Simmons M. N., Stephenson A. J., and Klein E. A., Natural history of biochemical recurrence after radical prostatectomy: risk assessment for secondary therapy, European Urology. (2007) 51, no. 5, 1175–1184, 2-s2.0-33947258834, https://doi.org/10.1016/j.eururo.2007.01.015.
- 4 Han M., Partin A. W., Zahurak M., Piantadosi S., Epstein J. I., and Walsh P. C., Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer, Journal of Urology. (2003) 169, no. 2, 517–523, 2-s2.0-0037304517, https://doi.org/10.1016/S0022-5347(05)63946-8.
- 5 Demark-Wahnefried W., Aziz N. M., Rowland J. H., and Pinto B. M., Riding the crest of the teachable moment: promoting long-term health after the diagnosis of cancer, Journal of Clinical Oncology. (2005) 23, no. 24, 5814–5830, 2-s2.0-24944541117, https://doi.org/10.1200/JCO.2005.01.230.
- 6 Reaven G. M., Banting lecture 1988. Role of insulin resistance in human disease, Diabetes. (1988) 37, no. 12, 1595–1607.
- 7 Ford E. S., Giles W. H., and Dietz W. H., Prevalence of the metabolic syndrome among US adults: findings from the Third National Health and Nutrition Examination Survey, Journal of the American Medical Association. (2002) 287, no. 3, 356–359, 2-s2.0-0037116641.
- 8 SmithS. C.Jr., Clark L. T., Cooper R. S., Daniels S. R., Kumanyika S. K., Ofili E., Quinones M. A., Sanchez E. J., Saunders E., and Tiukinhoy S. D., Discovering the full spectrum of cardiovascular disease: Minority Health Summit 2003: report of the Obesity, Metabolic Syndrome, and Hypertension Writing Group, Circulation. (2005) 111, no. 10, e134–e139, 2-s2.0-20144381796.
- 9 Hsing A. W., Sakoda L. C., and ChuaS.Jr., Obesity, metabolic syndrome, and prostate cancer, The American journal of clinical nutrition. (2007) 86, no. 3, s843–s857, 2-s2.0-40349085518.
- 10 Beebe-Dimmer J. L., Dunn R. L., Sarma A. V., Montie J. E., and Cooney K. A., Features of the metabolic syndrome and prostate cancer in African-American men, Cancer. (2007) 109, no. 5, 875–881, 2-s2.0-33847346957, https://doi.org/10.1002/cncr.22461.
- 11 Håheim L. L., Wisløff T. F., Holme I., and Nafstad P., Metabolic syndrome predicts prostate cancer in a cohort of middle-aged Norwegian men followed for 27 years, American Journal of Epidemiology. (2006) 164, no. 8, 769–774, 2-s2.0-33749471265, https://doi.org/10.1093/aje/kwj284.
- 12 Tuohimaa P., Tenkanen L., Syvälä H., Lumme S., Hakulinen T., Dillner J., and Hakama M., Interaction of factors related to the metabolic syndrome and vitamin D on risk of prostate cancer, Cancer Epidemiology Biomarkers and Prevention. (2007) 16, no. 2, 302–307, 2-s2.0-33847707281, https://doi.org/10.1158/1055-9965.EPI-06-0777.
- 13 Beebe-Dimmer J. L., Nock N. L., Neslund-Dudas C., Rundle A., Bock C. H., Tang D., Jankowski M., and Rybicki B. A., Racial differences in risk of prostate cancer associated with metabolic syndrome, Urology. (2009) 74, no. 1, 185–190, 2-s2.0-67649213956, https://doi.org/10.1016/j.urology.2009.03.013.
- 14 Rybicki B. A., Neslund-Dudas C., Nock N. L., Schultz L. R., Eklund L., Rosbolt J., Bock C. H., and Monaghan K. G., Prostate cancer risk from occupational exposure to polycyclic aromatic hydrocarbons interacting with the GSTP1 Ile105Val polymorphism, Cancer Detection and Prevention. (2006) 30, no. 5, 412–422, 2-s2.0-33750974796, https://doi.org/10.1016/j.cdp.2006.09.004.
- 15 Cleeman J. I., Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III), Journal of the American Medical Association. (2001) 285, no. 19, 2486–2497, 2-s2.0-0035897696.
- 16 Cronin A. M., Godoy G., and Vickers A. J., Definition of biochemical recurrence after radical prostatectomy does not substantially impact prognostic factor estimates, Journal of Urology. (2010) 183, no. 3, 984–989, 2-s2.0-75849145303, https://doi.org/10.1016/j.juro.2009.11.027.
- 17 Partin A. W. and Oesterling J. E., The clinical usefulness of prostate specific antigen: update 1994, Journal of Urology. (1994) 152, no. 5, part 1, 1358–1368, 2-s2.0-0028090544.
- 18 Wildman R. P., Muntner P., Reynolds K., McGinn A. P., Rajpathak S., Wylie-Rosett J., and Sowers M. R., The obese without cardiometabolic risk factor clustering and the normal weight with cardiometabolic risk factor clustering: prevalence and correlates of 2 phenotypes among the US population (NHANES 1999–2004), Archives of Internal Medicine. (2008) 168, no. 15, 1617–1624, 2-s2.0-49449106657, https://doi.org/10.1001/archinte.168.15.1617.
- 19 Freedland S. J., Amling C. L., Dorey F., Kane C. J., Presti J. C., Terris M. K., and Aronson W. J., Race as an outcome predictor after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database, Urology. (2002) 60, no. 4, 670–674, 2-s2.0-0036774936, https://doi.org/10.1016/S0090-4295(02)01847-2.
- 20 Hamilton R. J., Aronson W. J., PrestiJ. C.Jr., Terris M. K., Kane C. J., Amling C. L., and Freedland S. J., Race, biochemical disease recurrence, and prostate-specific antigen doubling time after radical prostatectomy: results from the SEARCH database, Cancer. (2007) 110, no. 10, 2202–2209, 2-s2.0-36049051624, https://doi.org/10.1002/cncr.23012.
- 21 Hammarsten J. and Högstedt B., Clinical, haemodynamic, anthropometric, metabolic and insulin profile of men with high-stage and high-grade clinical prostate cancer, Blood Pressure. (2004) 13, no. 1, 47–55, 2-s2.0-11144357623, https://doi.org/10.1080/08037050310025735.
- 22 Fitzpatrick A. L., Daling J. R., Furberg C. D., Kronmal R. A., and Weissfeld J. L., Hypertension, heart rate, use of antihypertensives, and incident prostate cancer, Annals of Epidemiology. (2001) 11, no. 8, 534–542, 2-s2.0-0035166782, https://doi.org/10.1016/S1047-2797(01)00246-0.
- 23 Rodriguez C., Jacobs E. J., Deka A., Patel A. V., Bain E. B., Thun M. J., and Calle E. E., Use of blood-pressure-lowering medication and risk of prostate cancer in the Cancer Prevention Study II Nutrition Cohort, Cancer Causes and Control. (2009) 20, no. 5, 671–679, 2-s2.0-67349175705, https://doi.org/10.1007/s10552-008-9280-0.
- 24 Touyz R. M., Reactive oxygen species, vascular oxidative stress, and redox signaling in hypertension: what is the clinical significance?, Hypertension. (2004) 44, no. 3, 248–252, 2-s2.0-4444329422, https://doi.org/10.1161/01.HYP.0000138070.47616.9d.
- 25 Hall W. D., Clark L. T., Wenger N. K., Wright J. T., Kumanyika S. K., Watson K., Horton E. W., Flack J. M., Ferdinand K. C., Gavin J. R., Reed J. W., Saunders E., and O′Neal W., The metabolic syndrome in African Americans: a review, Ethnicity and Disease. (2003) 13, no. 4, 414–427, 2-s2.0-10744232973.
- 26 Amling C. L., Blute M. L., Bergstralh E. J., Seay T. M., Slezak J., and Zincke H., Long-term hazard of progression after radical prostatectomy for clinically localized prostate cancer: continued risk of biochemical failure after 5 years, Journal of Urology. (2000) 164, no. 1, 101–105, 2-s2.0-0033935812.
